Larimar Therapeutics (NASDAQ:LRMR) Earns “Outperform” Rating from Leerink Partnrs

Larimar Therapeutics (NASDAQ:LRMRGet Free Report)‘s stock had its “outperform” rating reissued by Leerink Partnrs in a report issued on Wednesday, Zacks.com reports. Leerink Partnrs also issued estimates for Larimar Therapeutics’ FY2026 earnings at ($2.65) EPS, FY2027 earnings at ($2.41) EPS and FY2028 earnings at ($1.75) EPS.

Several other equities analysts have also commented on LRMR. Lifesci Capital restated an “outperform” rating on shares of Larimar Therapeutics in a report on Tuesday, February 20th. JMP Securities restated a “market outperform” rating and issued a $25.00 price objective on shares of Larimar Therapeutics in a report on Friday, March 15th. SVB Leerink initiated coverage on shares of Larimar Therapeutics in a report on Wednesday. They issued an “outperform” rating and a $25.00 price objective on the stock. Finally, Citigroup upped their price objective on shares of Larimar Therapeutics from $4.50 to $10.00 and gave the stock a “buy” rating in a report on Tuesday, February 13th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Larimar Therapeutics presently has an average rating of “Buy” and a consensus price target of $18.50.

Read Our Latest Research Report on LRMR

Larimar Therapeutics Price Performance

NASDAQ:LRMR opened at $7.72 on Wednesday. The firm has a market capitalization of $492.54 million, a price-to-earnings ratio of -9.08 and a beta of 0.93. The company’s 50-day moving average is $8.91 and its two-hundred day moving average is $5.52. Larimar Therapeutics has a 1-year low of $2.18 and a 1-year high of $13.68.

Insider Buying and Selling at Larimar Therapeutics

In other Larimar Therapeutics news, Director James E. Flynn bought 4,290,617 shares of the company’s stock in a transaction on Friday, February 16th. The stock was purchased at an average cost of $8.74 per share, for a total transaction of $37,499,992.58. Following the acquisition, the director now owns 6,151,406 shares of the company’s stock, valued at approximately $53,763,288.44. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Larimar Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Larimar Therapeutics by 1.9% in the fourth quarter. Vanguard Group Inc. now owns 1,455,243 shares of the company’s stock worth $6,621,000 after acquiring an additional 27,516 shares during the last quarter. Blue Owl Capital Holdings LP acquired a new stake in shares of Larimar Therapeutics in the fourth quarter worth approximately $15,536,000. Barclays PLC boosted its position in shares of Larimar Therapeutics by 601.6% in the fourth quarter. Barclays PLC now owns 35,291 shares of the company’s stock worth $160,000 after acquiring an additional 30,261 shares during the last quarter. Nuveen Asset Management LLC boosted its position in shares of Larimar Therapeutics by 8.0% in the fourth quarter. Nuveen Asset Management LLC now owns 38,492 shares of the company’s stock worth $175,000 after acquiring an additional 2,837 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its position in shares of Larimar Therapeutics by 5.9% in the fourth quarter. Bridgeway Capital Management LLC now owns 119,500 shares of the company’s stock worth $544,000 after acquiring an additional 6,700 shares during the last quarter. 91.92% of the stock is currently owned by hedge funds and other institutional investors.

Larimar Therapeutics Company Profile

(Get Free Report)

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

Featured Articles

Analyst Recommendations for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.